[go: up one dir, main page]

PE20130645A1 - Metodo para diagnosticar una repuesta al tratamiento en sujetos con esclerosis multiple - Google Patents

Metodo para diagnosticar una repuesta al tratamiento en sujetos con esclerosis multiple

Info

Publication number
PE20130645A1
PE20130645A1 PE2012002453A PE2012002453A PE20130645A1 PE 20130645 A1 PE20130645 A1 PE 20130645A1 PE 2012002453 A PE2012002453 A PE 2012002453A PE 2012002453 A PE2012002453 A PE 2012002453A PE 20130645 A1 PE20130645 A1 PE 20130645A1
Authority
PE
Peru
Prior art keywords
subject
treatment
interferon
irg
expression
Prior art date
Application number
PE2012002453A
Other languages
English (en)
Inventor
Richard A Rudick
Richard M Ransohoff
Original Assignee
Cleveland Clinic Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45348885&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20130645(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cleveland Clinic Foundation filed Critical Cleveland Clinic Foundation
Publication of PE20130645A1 publication Critical patent/PE20130645A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UN METODO PARA DETERMINAR LA EFICIENCIA DEL TRATAMIENTYO CON IFN-B A UN SUJETO CON ESCLEROSIS MULTIPLE QUE COMPRENDE: (i) ADMINISTRAR UNA DOSIS DE INTERFERON BETA AL SUJETO (ii) OBTENER UNA MUESTRA BIOLOGICA DEL SUJETO EN UN TIEMPO MENOR DE 12 HORAS DESDE LA ADMINISTRACION DEL INTERFERON. LA MUESTRA ES SANGRE DE LA CUAL SE AISLA EL ARN; (iii) DETERMINAR EL NIVEL DE EXPRESION DE AL MENOS UN GEN REGULADO POR INTERFERON (IRG) Y/O SU VARIANTE; (iv) ADMINISTRAR AL SUJETO UNA CANTIDAD TERAPEUTICAMENTE EFECTIVA DE AL MENOS UN AGENTE TAL COMO NATALIZUMAB, ADEMAS DE INTERFERON BETA SI LA EXPRESION DE AL MENOS UN IRG Y/O SU VARIANTE AUMENTA O DISMINUYE EN COMPARACION CON UN CONTROL. DICHO METODO PERMITE OBSERVAR EL AUMENTO O DISMINUCION DE LA EXPRESION DEL IRG Y/O SUS VARIANTES LO CUAL INDICA SI EL SUJETO RESPONDERA MAL AL TRATAMIENTO CON INTERFERON BETA.
PE2012002453A 2010-06-18 2011-06-17 Metodo para diagnosticar una repuesta al tratamiento en sujetos con esclerosis multiple PE20130645A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35626510P 2010-06-18 2010-06-18

Publications (1)

Publication Number Publication Date
PE20130645A1 true PE20130645A1 (es) 2013-07-03

Family

ID=45348885

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012002453A PE20130645A1 (es) 2010-06-18 2011-06-17 Metodo para diagnosticar una repuesta al tratamiento en sujetos con esclerosis multiple

Country Status (23)

Country Link
US (1) US20130089519A1 (es)
EP (1) EP2585100A4 (es)
JP (1) JP2013534419A (es)
KR (1) KR20130036046A (es)
CN (1) CN103140235A (es)
AU (1) AU2011268223B2 (es)
BR (1) BR112012032344A2 (es)
CA (1) CA2802999A1 (es)
CL (1) CL2012003571A1 (es)
CO (1) CO6670574A2 (es)
CR (1) CR20130018A (es)
DO (1) DOP2012000316A (es)
EA (1) EA201370003A1 (es)
EC (1) ECSP13012390A (es)
MA (1) MA34381B1 (es)
MX (1) MX2012015028A (es)
NI (1) NI201200188A (es)
PE (1) PE20130645A1 (es)
PH (1) PH12012502501A1 (es)
SG (1) SG186393A1 (es)
TN (1) TN2012000607A1 (es)
WO (1) WO2011159970A2 (es)
ZA (1) ZA201300019B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160265058A1 (en) * 2013-11-01 2016-09-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Diagnostic methods and kits for determining a personalized treatment regimen for a subject suffering from a pathologic disorder
WO2017066510A1 (en) * 2015-10-14 2017-04-20 Novozymes A/S Cleaning of water filtration membranes
CN108304912B (zh) * 2017-12-29 2020-12-29 北京理工大学 一种运用抑制信号实现脉冲神经网络监督学习的系统和方法
CN116068473A (zh) * 2021-10-29 2023-05-05 通用电气精准医疗有限责任公司 生成磁共振图像的方法和磁共振成像系统

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1369695B1 (en) * 2002-05-29 2006-03-15 Charité - Universitätsmedizin Berlin Method for identifying type-I interferon responsive MS patients by determining TRAIL expression
US20070237717A1 (en) * 2004-04-05 2007-10-11 Roland Martin Methods for Selection of Subjects for Multiple Sclerosis Therapy
US20100209914A1 (en) * 2007-05-25 2010-08-19 Ore Pharmaceuticals , Inc. Methods, systems, and kits for evaluating multiple sclerosis
EP2009440A1 (en) * 2007-06-01 2008-12-31 Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg Means and methods for classifying samples of multiple sclerosis patients.
JP2013505001A (ja) * 2008-09-16 2013-02-14 バイエル・ヘルスケア・エルエルシー 臨床サンプル中のインターフェロン応答（ｉｒｉｓ）

Also Published As

Publication number Publication date
CN103140235A (zh) 2013-06-05
AU2011268223B2 (en) 2014-05-29
DOP2012000316A (es) 2013-07-31
SG186393A1 (en) 2013-01-30
AU2011268223A1 (en) 2013-01-31
WO2011159970A2 (en) 2011-12-22
MX2012015028A (es) 2013-06-13
CO6670574A2 (es) 2013-05-15
CR20130018A (es) 2013-04-26
KR20130036046A (ko) 2013-04-09
CA2802999A1 (en) 2011-12-22
US20130089519A1 (en) 2013-04-11
TN2012000607A1 (en) 2014-04-01
EP2585100A2 (en) 2013-05-01
EP2585100A4 (en) 2013-11-06
EA201370003A1 (ru) 2013-06-28
BR112012032344A2 (pt) 2017-05-30
MA34381B1 (fr) 2013-07-03
JP2013534419A (ja) 2013-09-05
PH12012502501A1 (en) 2013-02-11
CL2012003571A1 (es) 2013-08-23
WO2011159970A3 (en) 2012-04-19
ECSP13012390A (es) 2013-04-30
NI201200188A (es) 2013-04-15
ZA201300019B (en) 2014-03-26

Similar Documents

Publication Publication Date Title
Vičić et al. Comprehensive insight into lichen planus immunopathogenesis
Vom Steeg et al. Androgen receptor signaling in the lungs mitigates inflammation and improves the outcome of influenza in mice
JP2015057427A5 (es)
AR069328A1 (es) Liberacion de rna interferente corto o sirna, intermediada por receptor de lipoproteina de baja densidad
UA117341C2 (uk) Кліщова композиція, яка включає хижого кліща та іммобілізовану жертву, що контактує зі стримуючим розвиток грибків агентом, і способи та застосування, пов'язані з використанням зазначеної композиції
MX347871B (es) Biomarcadores de citoquina como marcadores predictivos de respuesta clínica para acetato de glatirámero.
EA201300550A1 (ru) Фармацевтическая композиция, способы лечения и их применение
AR092981A1 (es) Biomarcadores predictivos de la respuesta clinica al acetato de glatiramero
Soldevilla et al. Mouse models for mycobacterium tuberculosis pathogenesis: show and do not tell
MX2020005235A (es) Celula humana transformada y uso de la misma.
BRPI0905687A8 (pt) composto da fórmula i ou i', composição farmacêutica, método de tratamento de um paciente com uma doença, uso do composto
PE20130645A1 (es) Metodo para diagnosticar una repuesta al tratamiento en sujetos con esclerosis multiple
BR112015022469A2 (pt) peptídeo ou análogo seu, composição, método para melhorar um sinal ou sintoma, método para estimular o crescimento de células, método para produção de uma população de células, método para aumentar o número de células, método para redução em um indivíduo diabético da tolerância à glicose debilitada, método para a promoção de neuroproteção ou regeneração nervosa, método para a promoção da regeneração, método para a inibição de inflamação, composição farmacêutica e uso de um peptídeo ou análogo seu
Li et al. Celastrol inhibits IL-1β-induced inflammation in orbital fibroblasts through the suppression of NF-κB activity
Senese et al. 3, 5 Diiodo-L-Thyronine (T2) promotes the browning of white adipose tissue in high-fat diet-induced overweight male rats housed at thermoneutrality
PE20090653A1 (es) Formulacion inmunogenica, porque comprende una cepa recombinante atenuada de mycobacterium, preferentemente la cepa recombinante bacilo de calmette y guerin (bcg), que expresa al menos una proteina o fragmento inmunogenico del virus respiratorio sinc
BR112014017141A2 (pt) método de tratamento de diabetes usando-se apolipoproteína a-iv não glicosilada
UY36099A (es) Laquinimod para el tratamiento de pacientes con esclerosis múltiple remitente recurrente (rrms) con un alto grado de discapacidad
CL2011003002A1 (es) Anticuerpo monoclonal o un fragmento del mismo que se une a la proteina m2-1 del virus respiratorio sincicial (vrs) humano; secuencias nucleotidicas; composicion farmaceutica; metodo de diagnostico de infeccion producida por vrs; kit; y uso de dicho anticuerpo para preparar un medicamento.
Yano et al. Static and dynamic hypergravity responses of osteoblasts and osteoclasts in medaka scales
Vargas et al. A designed host defense peptide for the topical treatment of MRSA-infected diabetic wounds
BR112013032911A2 (pt) leucotoxina e/d como um novo agente anti-inflamatório e microbicida
PE20210123A1 (es) Compuesto de anillo de metillactama y uso farmaceutico del mismo
Delam et al. Increased death anxiety in the elderly during Coronavirus disease 2019 (COVID-19) pandemic
Gong et al. Murine embryonic mesenchymal stem cells attenuated xerostomia in Sjögren-like mice via improving salivary gland epithelial cell structure and secretory function

Legal Events

Date Code Title Description
FD Application declared void or lapsed